MedTrace Logo

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

NCT07349758 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-13

No results posted yet for this study

Summary

The goal of this study is to evaluate the pharmacokinetics of a one-time dosing of two F/TAF tablets over a 14-day period.

Conditions

  • Healthy Volunteer
  • HIV Prevention

Interventions

DRUG

tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg

One-time dose of two F/TAF tablets

Sponsors & Collaborators

Principal Investigators

  • Sunil Solomon, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-06
Primary Completion
2027-01-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349758 on ClinicalTrials.gov